NASDAQ:ISEE IVERIC bio (ISEE) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$39.95▼$39.9550-Day Range$36.90▼$39.9552-Week Range$9.39▼$39.99VolumeN/AAverage Volume3.62 million shsMarket Capitalization$5.50 billionP/E RatioN/ADividend YieldN/APrice Target$25.75 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media IVERIC bio MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside35.5% Downside$25.75 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$789,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.77) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.70 out of 5 starsMedical Sector959th out of 961 stocksBiotechnology Industry12th out of 13 stocks 1.0 Analyst's Opinion Consensus RatingIVERIC bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 10 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.75, IVERIC bio has a forecasted downside of 35.5% from its current price of $39.95.Amount of Analyst CoverageIVERIC bio has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ISEE. Previous Next 0.0 Dividend Strength Dividend YieldIVERIC bio does not currently pay a dividend.Dividend GrowthIVERIC bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ISEE. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows3 people have added IVERIC bio to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IVERIC bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $789,000.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of IVERIC bio is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IVERIC bio are expected to grow in the coming year, from ($1.77) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IVERIC bio is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IVERIC bio is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIVERIC bio has a P/B Ratio of 9.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IVERIC bio (NASDAQ:ISEE) StockIVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.Read More ISEE Stock News HeadlinesJuly 11, 2023 | finance.yahoo.comAstellas Completes Acquisition of Iveric BioJune 30, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Hold Rating for IVERIC bio (ISEE)September 21, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.May 30, 2023 | seekingalpha.comIveric bio, Still A 5+% OpportunityMay 30, 2023 | finance.yahoo.comAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's WhyMay 23, 2023 | seekingalpha.comBayer, Amgen looked at Iveric before agreeing to Astellas sale - reportMay 17, 2023 | msn.comUnusual Call Option Trade in IVERIC bio (ISEE) Worth $1,780.50KMay 11, 2023 | fool.comIVERIC Bio (NASDAQ: ISEE)September 21, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.May 9, 2023 | msn.comTD Cowen Downgrades IVERIC bio (ISEE)May 2, 2023 | marketwatch.comSHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.May 2, 2023 | benzinga.comMoore Kuehn Encourages ISEE, MDWT, CBOF, and SGEN Investors to Contact Law FirmMay 1, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IVERIC bio, Inc. BuyoutMay 1, 2023 | benzinga.comCheck Out What Whales Are Doing With ISEEMay 1, 2023 | finance.yahoo.comAstellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'May 1, 2023 | finance.yahoo.comBiotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas PharmaMay 1, 2023 | finance.yahoo.comThese Stocks Are Moving the Most Today: First Republic, JPMorgan, Iveric Bio, SoFi, ON Semi, and MoreMay 1, 2023 | finance.yahoo.comFirst Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top StoriesMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether IVERIC bio, Inc. has obtained a Fair Price in its transaction with AstellasMay 1, 2023 | technews.tmcnet.comISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to ShareholdersMay 1, 2023 | marketwatch.comIveric Bio Shares Rise Premarket on Takeover by Astellas >ISEEMay 1, 2023 | msn.comIveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.May 1, 2023 | finance.yahoo.comJapan’s Astellas to buy US biotech group Iveric Bio for $5.9bnMay 1, 2023 | finance.yahoo.comThese Stocks Are Moving the Most Today: First Republic, JPMorgan, Iveric Bio, Carvana, Apple, and MoreMay 1, 2023 | finance.yahoo.comIveric Bio Agrees to $5.9 Billion Bid From Astellas. Buyers Are Hunting Biopharma Bargains.May 1, 2023 | markets.businessinsider.comAstellas Pharma To Acquire Iveric Bio In $5.9 Bln DealMay 1, 2023 | marketwatch.comAstellas Pharma: To Buy Iveric Bio for About $5.9B >4503.TO >4503.TO ISEESee More Headlines Receive ISEE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ISEE Company Calendar Last Earnings3/01/2023Today9/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ISEE CUSIPN/A CIK1410939 Webivericbio.com Phone(609) 474-6755FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Forecast$25.75 High Stock Price Forecast$35.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside-35.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-185,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.00% Return on Assets-46.15% Debt Debt-to-Equity Ratio0.20 Current Ratio15.53 Quick Ratio15.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.43 per share Price / Book9.02Miscellaneous Outstanding Shares137,780,000Free Float134,063,000Market Cap$5.50 billion OptionableOptionable Beta1.06 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Glenn P. Sblendorio M.B.A. (Age 67)CEO & Director Comp: $1.36MDr. Pravin U. Dugel M.D. (Age 59)Pres & Director Comp: $984.82kMr. David F. Carroll M.B.A. (Age 57)Sr. VP, CFO & Treasurer Comp: $725.55kMr. Keith Westby M.B.A. (Age 48)Sr. VP & COO Comp: $701.68kMr. Christopher Paul Simms (Age 48)Sr. VP & Chief Commercial Officer Comp: $715.01kDr. Samir C. Patel (Age 62)Co-Founder and Consultant Dr. Xiao-Ping Dai Ph.D.Chief Technical OfficerMs. Kathy GalanteSr. VP of Investor Relations & Corp. CommunicationsMr. Todd D.C. AndermanSr. VP, Chief Legal Officer & Corp. Sec.Ms. Amy R. SheehanSr. VP & Chief HR OfficerMore ExecutivesKey CompetitorsVeracyteNASDAQ:VCYTViking TherapeuticsNASDAQ:VKTXBioMarin PharmaceuticalNASDAQ:BMRNApellis PharmaceuticalsNASDAQ:APLS10x GenomicsNASDAQ:TXGView All CompetitorsInsiders & InstitutionsBarclays PLCBought 320,678 shares on 9/21/2023Ownership: 0.171%Bluefin Capital Management LLCBought 94,904 shares on 9/11/2023Ownership: 0.069%Wolverine Trading LLCSold 8,700 shares on 8/23/2023Ownership: 0.000%Goldman Sachs Group Inc.Bought 10,300 shares on 8/15/2023Ownership: 0.000%Worth Venture Partners LLCSold 25,700 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ISEE Stock - Frequently Asked Questions Should I buy or sell IVERIC bio stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last year. There are currently 10 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ISEE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISEE, but not buy additional shares or sell existing shares. View ISEE analyst ratings or view top-rated stocks. What is IVERIC bio's stock price forecast for 2023? 10 brokers have issued 1-year target prices for IVERIC bio's stock. Their ISEE share price forecasts range from $19.00 to $35.00. On average, they predict the company's stock price to reach $25.75 in the next twelve months. This suggests that the stock has a possible downside of 35.5%. View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts. How were IVERIC bio's earnings last quarter? IVERIC bio, Inc. (NASDAQ:ISEE) released its quarterly earnings data on Wednesday, March, 1st. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.10. During the same quarter in the previous year, the business posted ($0.29) EPS. What ETFs hold IVERIC bio's stock? ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB), AltShares Event-Driven ET (EVNT) and Vanguard Russell 2000 Growth ETF (VTWG).Vanguard Russell 2000 ETF (VTWO). What is Glenn Spina's approval rating as IVERIC bio's CEO? 6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of IVERIC bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC). What is IVERIC bio's stock symbol? IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE." Who are IVERIC bio's major shareholders? IVERIC bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (3.40%), TCG Crossover Management LLC (1.78%), Nuveen Asset Management LLC (0.74%), Segantii Capital Management Ltd (0.64%), Picton Mahoney Asset Management (0.00%) and Marshall Wace LLP (0.44%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel. View institutional ownership trends. What is IVERIC bio's stock price today? One share of ISEE stock can currently be purchased for approximately $39.95. How much money does IVERIC bio make? IVERIC bio (NASDAQ:ISEE) has a market capitalization of $5.50 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. How many employees does IVERIC bio have? The company employs 163 workers across the globe. How can I contact IVERIC bio? IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com. This page (NASDAQ:ISEE) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IVERIC bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.